目錄:MedChemExpress LLC>>生化試劑>> Rozanolixizumab | MCE
CAS | 1584645-37-3 | 純度 | 99.34% |
---|---|---|---|
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-P9979 | 應用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務。
CAS No. : 1584645-37-3
產(chǎn)品活性:Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.
研究領(lǐng)域:Others
作用靶點:Others
In Vitro: Rozanolixizumab binds to human FcRn and cynomolgus monkey FcRn with a similar affinity at both pH 6.0 (Kd 23 pM and 25 pM, human and cynomolgus monkey, respectively) and pH 7.4 (34 pM and 53 pM, human and cynomolgus monkey, respectively. Rozanolixizumab is observed to inhibit the recycling (IC50 0.41 nM) of human IgG by human FcRn-transfected MDCK cells in a dose-dependent manner. Recycling of IgG was also inhibits in cynomolgus monkey FcRn-transfected MDCK cells (IC50 0.98nM).
Rozanolixizumab causes an increase in intracellular IgG AF647.
In Vivo: Intravenous (IV) rozanolixizumab dosing in cynomolgus monkeys demonstrated non-linear pharmacokinetics indicative of target-mediated drug disposition; single IV rozanolixizumab doses (30 mg/kg) in cynomolgus monkeys reduced plasma IgG concentration by 69% by Day 7 post-administration. Daily IV administration of rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter) reduced plasma IgG concentrations in all cynomolgus monkeys, with low concentrations maintained throughout the treatment period (42 days).
相關(guān)產(chǎn)品:Antitumor agent-67 | Catechin 7-O-β-D-glucopyranoside | Carbobenzoxyproline | ATR-IN-9 | TBTDC | Peucenin 7-O-methyl ether | 6-Hydroxy-4-methylcoumarin | AMT-NHS | Nylidrin hydrochloride | D-(+)-Fucose | OVA Peptide (323-339) | Secretin (swine) | Bletilloside A | Transcriptional Intermediary Factor 2 (TIF2) (740-753) | Pep-1 (uncapped) | Aspochalasin M | Dihydrofuran-3(2H)-one | BPK-29 hydrochloride | pppApG | MEIS-IN-2 | 2′-O-Methyl-8-methyl guanosine | Altertoxin I | Lithospermoside | Acitazanolast | FLAG peptide | [Des-Tyr1]-Met-Enkephalin | α-Carotene | myo-Inositol trispyrophosphate hexa-triethylamine | Myt1-IN-2 | Simetride
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應用于新藥研發(fā)、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術(shù)服務;
• 設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。